Rheumatology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates
Annals of Rheumatic Diseases, 09/23/09

Dore RK et al. – This study extends evidence that denosumab increases BMD and reduces bone turnover in patients with RA and may provide a new therapeutic option for reducing systemic bone loss in patients with RA.

Methods

Subcutaneous placebo (n=75)
Denosumab 60mg (n=71)
Or denosumab 180mg (n=72) at baseline and 6 months
Serum procollagen 1N terminal peptide (P1NP)
Dual X-ray absorptiometry scans of the lumbar spine and hip
Serum type I C-telopeptide (sCTx-I)

Results

Denosumab treatment increased mean lumbar spine and hip BMD
Denosumab treatment reduced sCTx-I and P1NP versus placebo through 12 monthsli>
Is regardless of baseline BMD or marker levels or concomitant bisphosphonate or glucocorticoid use

<< Previous
Fatigue is a reliable, sensitive and unique outcome measure in...

Next >>
Cost-effectiveness of two therapeutic regimens of infliximab in...